pipette
ESEspañol

Preclinical and first-in-human evaluation of VG-3927/SAR448851, an oral small-molecule TREM2 agonist for Alzheimer’s disease

Borislav Dejanovic, Matthew D. Figley, Elizabeth F. Weisman, Beril Kiragasi, Frederick W. Gergits, Kelley Larson, Abigail J. Renoux, Raj Rajagovindan, Bhaumik A. Pandya, Jonathan B. Houze, Liyue Huang, François Gaudreault, Ryan O'Mara, Jade H. Clarkson, Marion T. Turnbull, Andreas Meier, Marco Colonna, Jessica Stromme, David L. Gray, Evan A. Thackaberry, Petra Kaufmann, Christian Mirescu

Peer-reviewed journalClaims a big stepReal-world use

In the authors' words

This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.

Main result
We report VG-3927, an oral, CNS-penetrant small-molecule TREM2 agonist that engages the transmembrane domains of TREM2 and its adaptor DAP12 to promote higher-order receptor complex formation and downstream signaling.

Appeared: Friday, October 16. Science Translational Medicine. Peer-reviewed journal.

DOI: 10.1126/scitranslmed.aec5740